Abstract Number: 1218 • 2019 ACR/ARP Annual Meeting
Monthly Dosing of ImmTOR Tolerogenic Nanoparticles Combined with Pegylated Uricase (Pegadricase) Enables Sustained Reduction of Acute Gout Flares in Symptomatic Gout Patients
Background/Purpose: Long term gout treatment focuses on reducing sUA levels, thus allowing MSU crystals to dissolve. Rapid dissolution of MSU crystals during initial phase of…Abstract Number: 2053 • 2019 ACR/ARP Annual Meeting
Risk of Non-vertebral Fracture in Gout Compared to Rheumatoid Arthritis
Background/Purpose: Gout is a common inflammatory arthritis, characterized by hyperuricemia leading to crystallization of uric acid in joints. Proinflammatory cytokines have been known as an…Abstract Number: 154 • 2019 ACR/ARP Annual Meeting
Enhancing Medicine Trainees’ Exposure to Gout Diagnosis and Management Through an Interprofessional Approach in the Primary Care Setting
Background/Purpose: Gout is common in primary care, though patients often have inadequate control or are referred to specialists for evaluation and management. This may be…Abstract Number: 343 • 2019 ACR/ARP Annual Meeting
Emergency Department Length of Stay in Patients with Acute Gout
Background/Purpose: Emergency department (ED) visits for acute gout increased by approximately 20% between 2006 and 2014 in the United States. (1) Reducing ED length of stay…Abstract Number: 1220 • 2019 ACR/ARP Annual Meeting
How Are Flares Reported in Long-term Gout Clinical Trials? A Content Analysis of Randomized Controlled Trials
Background/Purpose: Prevention of gout flares is a central concern to patients with gout. There are many potential ways that gout flares could be reported in…Abstract Number: 2054 • 2019 ACR/ARP Annual Meeting
Epidemiology of Gout in South Korea with the National Health Insurance Corporation Database
Background/Purpose: Gout is the most common inflammatory arthritis that results from chronic elevation of uric acid levels above the saturation point for monosodium urate crystal…Abstract Number: 257 • 2019 ACR/ARP Annual Meeting
Alcohol Use Hospitalizations in People with Gout, Osteoarthritis, Rheumatoid Arthritis, Fibromyalgia, and Low Back Pain Are Increasing: A Time-trends Study Using the U.S. National Data
Background/Purpose: Alcohol abuse and associated mortality is an important public health problem in the U.S. To our knowledge, limited data are available on alcohol use…Abstract Number: 346 • 2019 ACR/ARP Annual Meeting
Subtypes of Gout Based on Comorbidity Patterns Among Black Patients in the US General Population – Cluster Analysis of the National Health and Nutrition Examination Survey 2007-2016
Background/Purpose: Gout is a very prevalent condition associated with many metabolic and cardiorenal comorbidities. A few studies have investigated the comorbidity subtypes of gout patients…Abstract Number: 1226 • 2019 ACR/ARP Annual Meeting
Neutrophil Activation Identifies Patients with Active Polyarticular Gout – a Role for Neutrophil Biomarkers in Monitoring Gout Disease Activity and Severity
Background/Purpose: Neutrophils are key immune cells participating in host defense through several mechanisms, including the formation of neutrophil extracellular traps (NETs). Excessive neutrophil activation has…Abstract Number: 2058 • 2019 ACR/ARP Annual Meeting
Pharmacoepidemiology of Gout Treatment in Office-based Outpatient Care from 2009- 2016
Background/Purpose: Studies show that gout treatment remains suboptimal in the United States (US). Despite clear benefits for urate-lowering therapy (ULT) for chronic gout, surveyed physicians…Abstract Number: 294 • 2019 ACR/ARP Annual Meeting
Tendons Involvement at Early Onset of Gouty Arthritis, Ultrasonographic Study
Background/Purpose: Gout is the commonest form of inflammatory arthritis and is caused by the longstanding elevation of serum uric acid levels causing crystal deposits. monosodium…Abstract Number: 348 • 2019 ACR/ARP Annual Meeting
Patterns of Newer Gout Medication Use in a U.S. Electronic Health Record-Based Registry
Background/Purpose: A variety of newer gout therapies have been introduced in recent years, some with potential safety concerns. However, uptake of these therapies and associated…Abstract Number: 1227 • 2019 ACR/ARP Annual Meeting
A Neutrophil Signature Is Strongly Associated with Cardiovascular Risk in Gout
Background/Purpose: Patients with gout have an increased cardiovascular morbidity and mortality, not fully explained by traditional cardiovascular risk factors. Xanthine oxidase-induced oxidative stress, increased lipid…Abstract Number: 2077 • 2019 ACR/ARP Annual Meeting
Population Impact Attributable to Modifiable Risk Factors for Hyperuricemia and the Fallacy of the Variance Explained
Background/Purpose: In a seminal BMJ paper (Prior 1986), the Tokelau Island migrant study for gout and hyperuricemia concluded preventive strategies to modify body mass, diet…Abstract Number: 324 • 2019 ACR/ARP Annual Meeting
Adherence to Guideline Directed Management of Gout Among VA Providers
Background/Purpose: Gout is the most common inflammatory arthritis, affecting about 4% of the adult population in the United States. Management is often costly, with estimates around…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 24
- Next Page »